New antibody combo shows promise for Hard-to-Treat cancers
Disease control
Ongoing
This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …
Phase: PHASE1, PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC